Jason Franschman
About Jason Franschman
Jason Franschman is the Manager of Global Budget Development at BeiGene, with extensive experience in managing clinical trial budgets and contracts, particularly in the oncology sector.
Current Role at BeiGene
Jason Franschman is currently the Manager of Global Budget Development at BeiGene. He works remotely from Cambridge, MA. In this role, he is responsible for overseeing the development of global budgets, particularly focusing on financial planning and budget allocation for clinical trials and other key projects.
Previous Position at ICON plc
From 2018 to 2023, Jason Franschman served as Contracts Manager II at ICON plc. During his five-year tenure in a remote capacity based in Whippany, NJ, he was involved in managing and negotiating contracts, ensuring compliance, and supporting clinical operations through effective contract administration.
Experience in Financial Services
Jason Franschman has an extensive background in financial services. Between 2004 and 2007, he worked with UBS Financial Services as a Senior Stock Purchase Plan Administrator. Prior to that, he was involved in pension plan administration roles at Mellon HR Solutions, Morgan Stanley, and Milliman & Robertson Actuarial and Consulting from 2000 to 2004. These roles focused on managing pension plans, financial compliance, and client relationships.
Educational Background
Jason Franschman studied at the University of Richmond, where he earned a Bachelor of Science (BS) degree in Business Administration, Management, and Operations. He also obtained a BA in Finance from the University of Richmond's Robins School of Business. Both degrees were conferred between 1993 and 1997.
Career in Clinical Contract Management
Jason Franschman has significant experience in clinical contract management and budget oversight within the pharmaceutical industry. He has held positions such as Clinical Contract Specialist at PRA Health Sciences / Bayer and Financial Consultant at Biogen / Celeritas Solutions. His roles have consistently involved the management of clinical trial budgets and contracts, with a strong focus on the oncology sector.